Sage Therapeutics, a renowned biopharmaceutical company, recently reported its robust second-quarter 2025 results, showcasing an impressive 264% jump in revenue (GAAP) to $31.7 million. This surge, exceeding analysts’ expectations by 88.8%, was primarily driven by the remarkable growth of ZURZUVAE, Sage’s oral therapy for postpartum depression. The company also displayed a narrowed net loss of […]
Category: Sage Therapeutics
Maryland Drugmaker Acquires Sage Therapeutics for $795 Million
In a bold move that signals a new era of healthcare innovation, Sage Therapeutics, a company renowned for its relentless commitment to brain health and patient well-being, has been acquired by Supernus Pharmaceuticals, the Maryland-based drugmaker. This significant acquisition, which could reach a staggering $795 million, marks a pivotal milestone for both companies as they […]
Analysts Adjust Forecasts for Sage Therapeutics Post Acquisition
In a critical juncture for Sage Therapeutics, recent acquisition news has compelled analysts to recalibrate their projections. This significant pivot in the company’s growth trajectory has been influenced by Supernus Pharmaceuticals’ strategic acquisition of Sage. This move not only amplifies Sage’s growth profile but also injects diversity into its portfolio with the inclusion of a […]